(Q51617424)

English

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.

scientific article published on 4 January 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/21205990

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/21205990

0 references

Jo-Anne H. Young

9

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/21205990

Kent A Sepkowitz

3

object named as

Kent A Sepkowitz

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/21205990

author name string

Alison G Freifeld

1

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/21205990

Eric J Bow

2

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/21205990

Michael J Boeckh

4

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/21205990

James I Ito

5

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/21205990

Craig A Mullen

6

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/21205990

Issam I Raad

7

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/21205990

Kenneth V Rolston

8

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/21205990

John R Wingard

10

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/21205990

Infectious Diseases Society of Americaa

11

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/21205990

language of work or name

0 references

publication date

4 January 2011

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/21205990

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/21205990

52

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/21205990

4

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/21205990

427-431

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/21205990

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Management of fever in neutropenic patients with different risks of complications

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Beta-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Nosocomial spread of Pseudomonas aeruginosa isolates expressing the metallo-beta-lactamase VIM-2 in a hematology unit of a French hospital

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Emergence of MRSA in positive blood cultures from patients with febrile neutropenia--a cause for concern

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Early discharge of low-risk febrile neutropenic children and adolescents with cancer

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

New trends in patient management: risk-based therapy for febrile patients with neutropenia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Risk assessment and treatment of low-risk patients with febrile neutropenia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Detection of bloodstream infections in adults: how many blood cultures are needed?

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Optimal testing parameters for blood cultures

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Current blood culture methods and systems: clinical concepts, technology, and interpretation of results

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Peripheral vs. central blood cultures in patients admitted to a pediatric oncology ward

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Change of procalcitonin predicts clinical outcome of febrile episodes in patients with hematological malignancies.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Fever of unknown origin in febrile leukopenia.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer).

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Is monotherapy for febrile neutropenia still a viable alternative?

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections. Antibiotic Study Group.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North Ame

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Efficacy and safety of cefepime: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Mortality associated with cefepime therapy among neutropenic patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Carbapenem resistance in Canada

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Application of the IDSA guidelines for the use of antimicrobial agents in neutropenic patients: impact on reducing the use of glycopeptides

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Emergence of linezolid-resistant enterococci in a neutropenic patient

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

New antimicrobial agents for the treatment of Gram-positive bacterial infections

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Antimicrobial therapy of multidrug-resistant Streptococcus pneumoniae, vancomycin-resistant enterococci, and methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Viridans group streptococcal infections among children with cancer and the importance of emerging antibiotic resistance

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Septicemia and Shock Syndrome Due to Viridans Streptococci: A Case-Control Study of Predisposing Factors

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Streptococcus pneumoniae bacteremia in patients with cancer: disease characteristics and outcomes in the era of escalating drug resistance (1998-2002).

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Vancomycin-resistant enterococcal infections in bone marrow transplant recipients.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Lack of objectivity in the debate concerning third-generation oral contraceptives and venous thrombosis.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

High dose intravenous ciprofloxacin in febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

In vitro evaluation of the activity of two doses of Levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Pharmacodynamic assessment of the activity of high-dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Vancomycin does not benefit persistently febrile neutropenic people with cancer

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Neutropenic enterocolitis in adults: systematic analysis of evidence quality

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Imaging of the gastrointestinal complications of systemic chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Recovery from neutropenia can be predicted by the immature reticulocyte fraction several days before neutrophil recovery in autologous stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

The treatment of febrile neutropenia: from the Dark Ages to the present

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Electroconvulsive therapy. Pretreatment medical evaluation

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Prophylactic antimicrobial agents and the importance of fitness

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Prophylactic application of fluoroquinolones for selective decontamination of the gut: friend or foe.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use--safety report

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Impaired gut function as risk factor for invasive candidiasis in neutropenic patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Revisiting the Source of Candidemia: Skin or Gut?

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Empiric versus preemptive therapy in the management of febrile neutropenia in the patient being treated for hematologic malignancy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Fungal infections in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Histoplasmosis-associated cross-reactivity in the BioRad Platelia Aspergillus enzyme immunoassay

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Rapid diagnosis of invasive aspergillosis by antigen detection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Detection of Circulating Aspergillus fumigatus Galactomannan: Value and Limits of the Platelia Test for Diagnosing Invasive Aspergillosis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Laboratory diagnosis of invasive aspergillosis.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Mortality and cancer incidence among individuals with Down syndrome

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Antifungal agents--clinical pharmacokinetics and drug interactions

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Posaconazole therapeutic drug monitoring: a reference laboratory experience

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Cyclophosphamide metabolism is affected by azole antifungals

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Utility of influenza vaccination for oncology patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Respiratory virus infections in adults with hematologic malignancies: a prospective study.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Respiratory syncytial virus infection following hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Granulocyte colony-stimulating factors: finding the right indication

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Bloodstream infection in neutropenic cancer patients related to short-term nontunnelled catheters determined by quantitative blood cultures, differential time to positivity, and molecular epidemiological typing with pulsed-field gel electrophoresis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Differential quantitative blood cultures for the diagnosis of catheter-related bloodstream infections associated with short- and long-term catheters: a prospective study.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Value of differential quantitative blood cultures in the diagnosis of catheter-related sepsis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Staphylococcus aureus bacteremia in patients with Hickman catheters

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Central venous catheter-related bacteremia due to gram-negative bacilli: significance of catheter removal in preventing relapse

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Management of central venous catheters in patients with cancer and candidemia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Antibiotic-lock technique: a new approach to optimal therapy for catheter-related sepsis in home-parenteral nutrition patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Catheter-related Staphylococcus aureus bacteremia in cancer patients: high rate of complications with therapeutic implications.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Galactomannan in Bronchoalveolar Lavage Fluid

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Control of influenza A on a bone marrow transplant unit

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Galactomannan Does Not Precede Major Signs on a Pulmonary Computerized Tomographic Scan Suggestive of Invasive Aspergillosis in Patients with Hematological Malignancies

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ147

21 January 2018

Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance

1 reference

27 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1086/422009

Identifiers

10.1093/CID/CIQ147

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/21205990

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 April 2018

http://europepmc.org/abstract/MED/21205990

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51617424&oldid=2009312150"